Results of a Phase I/Ii Clinical Trial of BPX-101, a Novel Drug-Activated Dendritic Cell (DC) Vaccine for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.29.7_suppl.132
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2011
Authors
Publisher
American Society of Clinical Oncology (ASCO)